Case Report

A rare case report and literature overview: autoimmune polyglandular syndrome type II

Hasan Ergenc 1, Dilek Karakaya Arpacı 2, Ceyhun Varım 1*, Aysel Gurkan Tocoglu 1, Ali Tamer 1

1 Department of Internal Medicine, Faculty of Medicine, Sakarya University, Sakarya, Turkey
2 Department of Endocrinology, Bulent Ecevit University, Zonguldak, Turkey

Received: 30 November 2015
Accepted: 11 January 2016

*Correspondence:
Dr. Ceyhun Varım,
E-mail: ceyhunvarim@sakarya.edu.tr

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Autoimmune diseases are a heterogeneous group of diseases with chronic humoral immune response against different tissue formation. Autoimmune polyglandular syndrome (APS) is also characterized by multiple organ autoimmune dysfunction. 43-year-old male patient was admitted with complaints of anorexia, malaise, rapid darkening on skin under the sun. The patient, stating in his medical background that levothyroxine TB with the diagnosis of hypothyroidism was started three years ago, had hypotension and hyperpigmentation. Hyponatremia, hyperkalemia, autoimmune hypothyroidism, primary adrenal insufficiency and atrophic gastritis was detected in examinations, significant improvements were observed in the general condition of the patient, on whom glucocorticoids, and then levothyroxine TB replacement treatments were applied, and in blood pressure and laboratory parameters. Therefore, other organ autoimmune should be sought in patients admitted with any autoimmune disease and be considered in follow-ups. We aimed to review the literature about APS and remind APS by this case.

Keywords: Autoimmune polyglandular syndrome, Chronic autoimmune thyroiditis, Adrenal insufficiency

INTRODUCTION

Organ-specific autoimmune diseases are associated with the contribution of environmental factors in people with a genetic predisposition. 1 These individuals constitute specific cellular and humoral response against their own tissues, and one or more organs may be affected by this situation. However, there are still many questions remaining pathophysiologically unanswered about autoimmunity in APS development. Previously it was thought that organs from the same embryonic origin and sharing common specific antigens were affected. However the fact that the adrenal gland, and the thyroid and pancreatic glands, which are affected in APS-2, have respectively mesodermal and endodermal origins, does not verify this hypothesis. Furthermore, why autoimmunity focuses solely on the proteins in endocrine tissues but not on the proteins in the organs originating from the same germ layer and why multiple organs are affected at different times cannot be explained sufficiently. 2,3 Autoimmune polyglandular syndrome (APS) is also characterized by multiple organ autoimmune dysfunction. It is classified into four main types: APS type I; begins in childhood and is characterized by mucocutaneous candidiasis, hypoparathyroidism and adrenal insufficiency. APS type II or Schmidt syndrome; is more common in the adult population. It is often characterized by primary adrenal insufficiency, Graves’ disease or autoimmune hypothyroidism, diabetes mellitus type I and primary hypogonadism. APS type III; is characterized by insulin dependent diabetes mellitus that develops without
Addison's disease and autoimmune thyroiditis disease, and APS type IV are the combinations which do not include the features of the previously reported groups. We aimed to present the 43-year-old male patient who was diagnosed with APS type II (primary adrenal insufficiency, autoimmune thyroiditis and atrophic gastritis) in this case.

CASE REPORT

The 43-year-old male patient was admitted to endocrinology clinic with complaints of anorexia, malaise, rapid darkening on skin under the sun. It is stated in his medical history that he was diagnosed with hypothyroidism; levothyroxine treatment was started 3 years ago. Due to the patient's continuing complaints under treatment with levothyroxine, the drug treatment was discontinued and the patient, who had not received any treatment for two years, was admitted to the clinic. In the patient's physical examination, his height was 172 cm, weight: 70 kg, body mass index (BMI): 24 kg/m², TA: 90/70 mmHg, pulse: 78 min and his thyroid gland was grade 1b palpable. Hyperpigmentation was present in the incision in the arm, the body curves and oral mucosa was normal. Other systemic examination was normal. In the tests performed; it was found that TSH was 35 µIU/ml (0.35 to 4.4µIU/ml); FT3 was 2.51 pmol/L (2.63-5.7 pmol/L), FT4 was 9.1 pmol/L (9-19 pmol/L), AntiTPO (antithyroid peroxidase hormone) was 498 (0-5.6) IU/ml; AntiTg (antithyroglobulin) was 118 (0-4.11) IU/ml; serum Na(sodium) was 132 (136-145) mmol/L and potassium was 5.1-5.5 (3.5 to 5.1) mmol/L, glucose was 94 (80-100) mg/dl; serum creatinine level was 0.8 mg/dl (0.5-0.9); calcium 9 mg/dl (8.8-10.2); PTH (parathormone) was 35 pg/ml (10-72); serum cortisol was 0.8-1.0 µg/dL (3-19) and ACTH was 515 pg/ml (15-50) and serum testosterone was 7.68 ng/ml (1.66-8.77). The patients with hypocortisolemia were admitted to the endocrinology clinic. The cortisol values at 30th and 60th mins were 0.9 mcg/dl and 1 mcg/dl in short ACTH test (250 micrograms), respectively. ACTH level was found to be 515 pg/mL. No pathology was detected in the surrenal MR performed. The medical history and physical examination of the patient is incompatible with tuberculosis, his chest X-ray was normal. With the diagnosis of primary adrenal insufficiency and primary hypothyroidism, first hydrocortisone was started at stress doses, and then the dose was reduced to physiological dose (20 mcg/day). Fludrocortisone (0.05 mg / day) treatment was started on the patient with hypotension, hyponatremia and hyperpotasemia. Thyroid replacement therapy was gradually started 3 days after hydrocortisone replacement, and it was gradually increased up to 100 mcg/day. The thyroid ultrasound of the patient was consistent with chronic thyroiditis and Hashimoto's thyroiditis. In the tests of the patient screened in terms of polyglandular endocrinopathy, it was detected that serum vitamin B12 level was 399 pg/ml (normal 145-914) and anti-parietal cell antibody was 1/320 positive. Since the anti-parietal cell antibody was positive, an upper gastrointestinal endoscopy was performed on the patient, and atrophic gastritis was revealed. The clinical and laboratory findings of the patient were incompatible with diabetes mellitus vitiligio and hypogonadism. The other autoimmune disease markers; antinuclear antibodies (ANA), Extractible Nuclear Antigen (ENA) and celiac antibodies were negative. In the follow-up of the patient, Na was 138 mEq/L, K was 4.1mEq/L and TA was 120/80 mmHg. The patient, whose general condition was stable, was screened with routine endocrinology polyclinic follow-up.

DISCUSSION

The organ-specific autoimmune diseases characterized by lymphocytic infiltration and specific autoantibodies result in endocrine hyperfunction or hypofunction. Clinical signs of the disease are usually limited to a gland. In addition; not infrequently, individual or familial infiltration of multiple endocrine glands can also be seen. APS is divided into four groups by Betterle et al. Type 3 is sub-divided into four groups including; 3A, 3B, 3C, 3D (Table 1).4

Looking at the history of the disease, the relationship between thyroiditis and Addison's disease was first revealed by Schmidt in 1926. In 1964, Carpenter et al. added type 1 diabetes to the syndrome.

APS type 2 is associated with genes which are generally transmitted with familial inheritance and that regulate the antigen presentation to T cells. APS type 2 is usually hereditary in families associated with characteristic HL.3 However, it is also known that environmental factors play an important role in the emergence of the disease.7 There are studies suggesting that abnormal expression of the gene encoding Cytotoxic T-lenfositanti-j4 (CTLA-4) predisposes to autoimmune polyglandular syndrome type 2.

Autoimmune polyglandular syndrome type 2, is more common than Type 1, and typically more common in adults. Insulin-dependent diabetes mellitus and thyroid dysfunction (autoimmune hypothyroidism or Graves' disease) are the most common clinical presentations. Addison's disease is the third major component of these disorders.6 Disorders of other endocrine glands may clinically develop in the majority of the patients with Addison's disease. In our case also; Addison's disease was accompanied by autoimmune hypothyroidism and atrophic gastritis.7 Among the components of polyglandular syndrome type 2 that are less frequent, are primary hypogonadism and hypophysitis.8 Additionally, pernicious anemia, vitiligio and celiac disease are the other rare diseases that may be associated with this syndrome.9
**Table 1: Classification of autoimmune polyglandular syndrome.**

| APS 1                      | APS 2                                                                 | APS 3                                                                 | APS 4                                                                 |
|---------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Chronic candidiasis       | Addison’s disease should certainly be present                           | Autoimmune thyroid disease should certainly be present                | APS involvement not meeting the definitions of APS type 1, 2, 3       |
| And/or chronic hypoparathyroidism | Autoimmune thyroid diseases                                              | Gastrointestinal or hepatic autoimmune diseases                      |                                                                       |
| And/or Addison’s disease  | And/or type 1 diabetes mellitus                                         | Skin, neural or neuromuscular autoimmune diseases                     |                                                                       |
|                           | Type 1 DM                                                              | Autoimmune thrombocytopenia                                          | Systemic lupus erythematosus                                          |
|                           | Celiac disease                                                         | Autoimmune Hemolytic anaemia                                         | Discoid lupus erythematosus                                           |
|                           | Adenosine and neurohypophysis diseases                                  | Anti-phospholipid syndrome                                            | Rheumatoid arthritis                                                  |
|                           | Premature ovarian failure                                               | Myasthenia Gravis                                                    | Seronegative arthritis                                                |
|                           | Hirata syndrome                                                        | Stiff-Man Syndrome                                                  | Systemic sclerosis                                                    |
|                           |                                                                         | Multiple Sclerosis                                                  | Sjogren’s syndrome                                                   |
|                           |                                                                         |                                                                     | Werlhof syndrome                                                     |
|                           |                                                                         |                                                                     | Antiphospholipid syndrome                                             |
|                           |                                                                         |                                                                     | Vasculitis                                                           |

Two or more of the diseases above should be present

Addison’s diseases should especially be taken into consideration in the presence of multiple autoimmune diseases, and patients should be screened in a detailed manner in this respect also.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**

1. Saygılı F. Autoimmune endocrine diseases. Türkiye Klinikleri J Endocrin Special Topics, 2010;3:1-5.
2. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137:225-33.
3. Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed Ateneo Parmense. 2003;74:9-33.
4. Dilek E, İşcan B, Eküku G, Tütüncüler F. Retrospective evaluation of the cases diagnosed as
Hashimoto’s Thyroiditis. Çocuk Dergisi. 2000;11:73-7.

5. Gibson DS, Banha J, Penque D, Costa L, Conrads TP, Cahill DJ, et al. Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders. J Proteomics. 2010;18:1045-60.

6. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88:2983-92.

7. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore). 1981;60:355-62.

8. Ward L, Paquette J, Seidman E. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J ClinEndocrinolMetab. 1999;84:844-52.

9. Yötem A. Poliglandüler endokrin yetmezlikler. In: Özata M, Yötem A, eds. Endokrinoloji Metabolizma ve Diyabet. baskı. İstanbul: İstanbul medikal yayın. 2006:579-82.

10. Jaume JC. Endocrine autoimmunity. In: Greenspan FS, Gardner DG, eds. Basic and Clinical Endocrinology. 7th ed. USA: McGraw-HillCompanies. 2004:85-105.

Cite this article as: Ergenc H, Arpaci DK, Varım C, Tocoglu AG, Tamer A. A rare case report and literature overview: autoimmune polyglandular syndrome type II. Int J Adv Med 2016;3:138-41.